200400-14-2

Basic information

• Product Name: 2-(CYCLOHEXYLMETHOXY)-1-ETHANAMINE
• Synonyms: 2-(CYCLOHEXYLMETHOXY)-1-ETHANAMINE
• CAS NO: 200400-14-2
• Molecular Formula: C₉H₁₉NO
• Molecular Weight: 157.25
• Mol File: 200400-14-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(CYCLOHEXYLMETHOXY)-1-ETHANAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(CYCLOHEXYLMETHOXY)-1-ETHANAMINE(200400-14-2)
• EPA Substance Registry System: 2-(CYCLOHEXYLMETHOXY)-1-ETHANAMINE(200400-14-2)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 200400-14-2(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2-(CYCLOHEXYLMETHOXY)-1-ETHANAMINE is used as a building block in organic synthesis for its ability to form a variety of chemical compounds. Its versatile structure allows for the creation of new molecules with potential applications in various industries.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2-(CYCLOHEXYLMETHOXY)-1-ETHANAMINE is utilized as a key component in the development of new pharmaceutical compounds. Its unique structure and reactivity make it a valuable asset in the design and synthesis of novel drugs with potential therapeutic benefits.
Used in Drug Development:
2-(CYCLOHEXYLMETHOXY)-1-ETHANAMINE is used as a chemical intermediate in the production of various pharmaceutical compounds. Its presence in the synthesis process contributes to the formation of drugs with specific therapeutic properties, enhancing their efficacy and safety.
Used in Therapeutic Agent Research:
This chemical is known to exhibit some biological activity, making it a subject of interest for researchers exploring its potential as a therapeutic agent. Studies are conducted to understand its interactions with biological systems and its possible applications in treating specific conditions or diseases.
Used in Chemical Intermediate Production:
2-(CYCLOHEXYLMETHOXY)-1-ETHANAMINE serves as a crucial chemical intermediate in the synthesis of other compounds. Its role in the production process is essential for creating a wide range of products across different industries, highlighting its versatility and importance in chemical manufacturing.

Upstream product

• 88964-98-1 2-(cyclohexylmethoxy)ethanol 
• 100-49-2 cyclohexylmethyl alcohol 
• 344298-63-1 cyclohexylmethoxy-acetic acid methyl ester 

Downstream Products

• 200400-65-3 N-<2-(cyclohexylmethoxy)ethyl>-2-<4-(3-pyridylcarbonyl)phenyl>-4-oxazolecarboxamide 

Relevant articles and documents

Carbamoyl substituted heterocycles

This invention relates to carbamoyl substituted heterocycles which are ω-phenyl-ω-(3-pyridyl)-ω-alkenoic acid derivatives bearing a carbamoyl substituted oxazolyl or oxazolinyl group on the phenyl ring and which demonstrate utility for thromboxane receptor antagonism and/or thromboxane synthase inhibition, as well as pharmaceutical formulations containing them, methods for their use, and processes and intermediates for their preparation.

PREPARATION OF SUBSTITUTED ALKENOIC ACIDS

This invention relates to a highly selective process for preparation of E-ω-phenyl-ω-(3-pyridyl)-ω-alkenoic acid derivatives bearing a carbamoyl substituted oxazolyl or oxazolinyl group on the phenyl ring which demonstrate utility for thromboxane receptor antagonism and/or thromboxane synthase inhibition, as well as to intermediates therefor.

Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 3. Synthesis and biological activities of oxazolecarboxamide-substituted ω-phenyl-ω-(3-pyridyl)alkenoic acid derivatives and related compounds

A novel series of oxazolecarboxamide-substituted ω-phenyl-ω-(3- pyridyl)alkenoic acid derivatives was discovered as potent dual-acting agents to block the TXA2 receptor and to inhibit the thromboxane synthase (TRA/TSI). Synthesis, structure-activity relationship (SAR), and in vitro and in vivo pharmacology of this series of compounds are described. Modification of the series revolved around the oxazole moiety to increase the hydrophilicity of the compounds and to correlate the biological activity with lipophilicity of the compounds. The most potent in the series was (E)-7-[4- [4-[[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept- 6-enoic acid (14) with K(d) = 9.9 ± 0.4 nM for the thromboxane receptor antagonism and IC50 = 55.0 ± 17.9 nM for thromboxane synthase inhibition. The compound 14 was a selective TRA/TSI which exhibited desirable characteristics for oral activity, 'shunt' effect to elevate PGI2 level, and absence of agonist activity.